Age Stratification and Prognostic Factor Analysis in Pediatric Differentiated Thyroid Cancer.


Journal

The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378

Informations de publication

Date de publication:
Nov 2024
Historique:
revised: 03 05 2024
received: 17 07 2023
accepted: 06 06 2024
medline: 13 10 2024
pubmed: 13 10 2024
entrez: 10 10 2024
Statut: ppublish

Résumé

Differentiated thyroid cancer (DTC) is rare in the pediatric population. It remains unclear whether younger children are at greater risk of more aggressive disease. We aimed to identify prognostic factors for aggressive pediatric DTC and to define an appropriate age stratification. This retrospective cohort study included all patients aged 18 years or less who were treated for DTC between 1985 and 2021 in a tertiary medical center and were followed up for a minimum of 1.5 years after treatment. Seventy-eight patients were included, all diagnosed with papillary thyroid carcinoma: 30 (38.5%) low-risk, 21 (26.9%) intermediate-risk, and 27 (34.6%) high-risk according to the American Thyroid Association (ATA) risk stratification. The mean duration of follow-up was 11.8 ± 7.8 years. No evidence of disease was documented in 52 patients (66.7%) at 1-year post-treatment and 64 patients (82.1%) at the end of follow-up. On analysis by age, evidence of disease at 1-year post-treatment was found in 66.7% of children younger than 11 years, compared to 25.4% of older children (p = 0.002). There was no significant difference by age in evidence of disease at the last follow-up (p = 0.453). Patients aged <11 years at diagnosis were associated with more aggressive disease features on histopathologic examination, metastatic disease, and high ATA risk level. Patients aged <8 years were associated with more frequent bilateral disease and extrathyroidal extension. Pediatric DTC patients who are younger than 11 years at diagnosis have more aggressive disease features and a lower early remission rate than older patients. Nevertheless, their long-term outcome is satisfactory. 4-retrospective cohort study Laryngoscope, 134:4818-4825, 2024.

Identifiants

pubmed: 39387721
doi: 10.1002/lary.31592
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4818-4825

Informations de copyright

© 2024 The American Laryngological, Rhinological and Otological Society, Inc.

Références

Christison‐Lagay E, Baertschiger RM. Management of differentiated thyroid carcinoma in pediatric patients. Surg Oncol Clin N Am. 2021;30(2):235‐251. https://doi.org/10.1016/j.soc.2020.11.013.
Lazar L, Lebenthal Y, Segal K, et al. Pediatric thyroid cancer: postoperative classifications and response to initial therapy as prognostic factors. J Clin Endocrinol Metab. 2016;101(5):1970‐1979. https://doi.org/10.1210/jc.2015-3960.
Stack BC Jr, Twining C, Rastatter J, et al. Consensus statement by the American Association of Clinical Endocrinology (AACE) and the American head and neck society endocrine surgery section (AHNS‐ES) on pediatric benign and malignant thyroid surgery. Head Neck. 2021;43(4):1027‐1042. https://doi.org/10.1002/hed.26586.
Francis GL, Waguespack SG, Bauer AJ, et al. American Thyroid Association guidelines task force. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25(7):716‐759. https://doi.org/10.1089/thy.2014.0460.
Lazar L, Lebenthal Y, Steinmetz A, Yackobovitch‐Gavan M, Phillip M. Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre‐pubertal children and adolescents. J Pediatr. 2009;154(5):708‐714. https://doi.org/10.1016/j.jpeds.2008.11.059.
Ben Arush MW, Stein ME, Perez Nahum M, Zidan J, Kuten A. Pediatric thyroid carcinoma: 22 years of experience at the northern Israel oncology center (1973–1995). Pediatr Hematol Oncol. 2000;17(1):85‐92. https://doi.org/10.1080/088800100276695.
Popovtzer A, Shpitzer T, Bahar G, Feinmesser R, Segal K. Thyroid cancer in children: management and outcome experience of a referral center. Otolaryngol Head Neck Surg. 2006;135(4):581‐584. https://doi.org/10.1016/j.otohns.2006.04.004.
Sapuppo G, Hartl D, Fresneau B, et al. Differentiated thyroid cancer in children and adolescents: long term outcome and risk factors for persistent disease. Cancers (Basel). 2021;13(15):3732. https://doi.org/10.3390/cancers13153732.
Thiesmeyer JW, Egan CE, Greenberg JA, et al. Prepubertal children with papillary thyroid carcinoma present with more invasive disease than adolescents and young adults. Thyroid. 2023;33(2):214‐222. https://doi.org/10.1089/thy.2022.0098.
He Y, Li H, Wang K, et al. Fourteen years old as the best age cutoff to differentiate prepubertal from pubertal papillary thyroid carcinoma. Head Neck. 2023;45(1):85‐94. https://doi.org/10.1002/hed.27208.
Galuppini F, Vianello F, Censi S, et al. Differentiated thyroid carcinoma in pediatric age: genetic and clinical scenario. Front Endocrinol (Lausanne). 2019;7(10):552. https://doi.org/10.3389/fendo.2019.00552.
Sugino K, Nagahama M, Kitagawa W, et al. Cutoff age between pediatric and adult thyroid differentiated cancer: is 18 years old appropriate? Thyroid. 2021;32(2):145‐152. https://doi.org/10.1089/thy.2021.0255.
Brady C, Manning SC, Rudzinski E, et al. Clinical outcomes of diffuse Sclerosing variant papillary thyroid carcinoma in pediatric patients. Laryngoscope. 2022;132(5):1132‐1138. https://doi.org/10.1002/lary.29926.
Yeker RM, Shaffer AD, Viswanathan P, et al. Chronic lymphocytic thyroiditis and aggressiveness of pediatric differentiated thyroid cancer. Laryngoscope. 2021;132(8):1668‐1674. https://doi.org/10.1002/lary.29908.
Hacıhamdioğlu B, Oçal G, Berberoğlu M, et al. The evaluation of thyroid carcinoma in childhood and concomitance of autoimmune thyroid disorders. J Pediatr Endocrinol Metab. 2014;27(9–10):901‐908. https://doi.org/10.1515/jpem-2013-0273.
Ritter A, Hod R, Reuven Y, et al. Role of intraoperative recurrent laryngeal nerve monitoring for pediatric thyroid surgery: comparative analysis. Head Neck. 2021;43(3):849‐857. https://doi.org/10.1002/hed.26544.

Auteurs

Ophir Winder (O)

Department of Otolaryngology, Head and Neck Surgery, Rabin Medical Center and Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Liora Lazar (L)

Institute of Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Roy Hod (R)

Department of Otolaryngology, Head and Neck Surgery, Rabin Medical Center and Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Thomas Shpitzer (T)

Department of Otolaryngology, Head and Neck Surgery, Rabin Medical Center and Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Aviram Mizrachi (A)

Department of Otolaryngology, Head and Neck Surgery, Rabin Medical Center and Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Gideon Bachar (G)

Department of Otolaryngology, Head and Neck Surgery, Rabin Medical Center and Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH